Apimeds Pharmaceuticals US, Inc. and Lōkahi Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) Division of Anesthesiology, Addiction Medicine and Pain Medicine (DAAP) has confirmed a Type C meeting to discuss LT-100 (Apitox), a non-opioid biologic candidate being developed for the treatment of the signs and symptoms of osteoarthritis (OA). The meeting will be conducted via teleconference on Monday, May 4, 2026.

"LT‑100, which is currently undergoing manufacturing process enhancements, is taking an important next step toward clinical advancement as we work to align with the FDA on future development strategies,” said Erik Emerson, CEO of Lokahi Therapeutics.

The scheduled interaction follows the recent submission of a Type C meeting request and represents an important step in the coordinated U.S. regulatory strategy for LT-100. The meeting is intended to support alignment with the FDA on key development considerations and the overall path forward for the program in the U.S.

LT-100 is pure honeybee venom, with a long history of clinical investigation. The product was originally developed and approved in South Korea, where it was approved for marketing in South Korea by the Korean Food and Drug Administration (KFDA; now the Ministry of Food and Drug Safety [MFDS]). Apimeds and Lōkahi Therapeutics are now advancing the program in the U.S. by integrating its historical data with rigorous development standards.

“LT‑100, which is currently undergoing manufacturing process enhancements, is taking an important next step toward clinical advancement as we work to align with the FDA on future development strategies,” said Erik Emerson, President of Apimeds and Chief Executive Officer of Lōkahi Therapeutics. “LT‑100 has broad therapeutic potential, and we believe that updating the route of administration to reflect current clinical best practices, while reducing burden for patients and providers, positions the program well for continued progress.”

“This meeting reflects the extensive analytical and development work undertaken to prepare LT-100 for continued advancement,” said Susan Kramer, DrPH, SVP of Development at Lōkahi Therapeutics. “Our team has carefully evaluated the nonclinical, clinical, and manufacturing components of the program to ensure a cohesive and scientifically rigorous development plan. Early and constructive engagement with the FDA is a critical step in responsibly advancing this asset.”